Floatz logo

Bryostatin 1

Recurrent Adult Diffuse Large Cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

271 Active assets in the Recurrent Adult Diffuse Large Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB
FILGRASTIM
Ruijin Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Bryostatin 1 is also rated in:

Recurrent Adult Diffuse Mixed Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →